CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
(DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple...
Phase 3
Toronto, Ontario, Canada and 145 other locations
The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.
Phase 1, Phase 2
Toronto, Ontario, Canada and 48 other locations
versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM).The study is anticipated to randomize app...
Phase 3
Toronto, Ontario, Canada and 59 other locations
1b/2, open label, multi-center, Clinical Study of Chimeric Antigen Receptor T Cells targeting BCMA in patients with relapsed and or refractory multiple...
Phase 1, Phase 2
Toronto, Ontario, Canada and 12 other locations
phases, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma...
Phase 1, Phase 2
Toronto, Ontario, Canada and 24 other locations
versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple...
Phase 3
Toronto, Canada and 126 other locations
as a single-agent in the setting of relapsed and/or refractory multiple myeloma (R/R MM). The study will be conducted in two parts:...
Phase 1
Toronto, Ontario, Canada and 14 other locations
Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone ma...
Phase 1
Hamilton, Ontario, Canada and 38 other locations
(LD-Dex) (Cohort B) in subjects with relapsed or refractory multiple myeloma who have received a first or second line treatment of ...
Phase 2
Toronto, Ontario, Canada and 48 other locations
determine the Recommended Phase 2 Dose and clinical benefit of elranatamab in combination with other anti-cancer therapies in participants with multiple...
Phase 2
Toronto, Ontario, Canada and 40 other locations
Clinical trials
Research sites
Resources
Legal